HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target

Benzinga · 2d ago
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $45 price target.